Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065926 | 0.91 | CTSS (0.59) | CTSSCTSL | |
| SCHEMBL3071883 | 0.88 | CTSS (0.56) | CTSS | |
| SCHEMBL3066345 | 0.88 | CTSS (0.53) | CTSSCTSL | |
| SCHEMBL3066712 | 0.88 | CTSS (0.54) | CTSS | |
| SCHEMBL3071736 | 0.87 | CTSS (0.56) | CTSSCTSL | |
| SCHEMBL3073598 | 0.85 | CTSS (0.58) | CTSS | |
| SCHEMBL29417402 | 0.85 | CTSS (0.78) | CTSSCTSL | |
| SCHEMBL696061 | 0.85 | CTSS (0.78) | CTSSCTSL | |
| SCHEMBL3064882 | 0.85 | CTSS (0.57) | CTSSCTSL | |
| SCHEMBL3055657 | 0.85 | CTSS (0.57) | CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | claimed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | claimed |
| US-10689339-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20180362461-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-12-20 | — | — | US | disclosed |
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362461-A1 | NOVEL PYRROLIDINE DERIVATIVES | ARG2, PYCR1, ARG1 | CTSS 2797/4885CTSL 1387/4885 |
| US-10689339-B2 | Pyrrolidine derivatives | PYCR1, AVPR2, ARG2 | CTSS 2385/4885CTSL 1147/4885 |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | CTSS 1542/4885CTSL 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.